Buy The Dip In Gilead: Why A Decrease In Quarterly Sovaldi Revenue Is Expected
- Gilead is a tremendous value especially after an 8% drop in the past 2 weeks.
- Sovaldi sales in the third quarter are predicted to decrease slightly prior to the much improved regimen of Sofosbuvir/Ledipasvir which is up for FDA approval next month.
- Trust Gilead’s management decision to discount Sovaldi to 90 developing countries. There decisions have provided an upside of 500% returns since 2011.
- At a price of $102, Gilead is trading at 11x expected 2015 earnings.